CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that results from preclinical and clinical studies of ACE-011 will be presented at the annual meetings of the American Society of Hematology and the San Antonio Breast Cancer Symposium over a three day period starting on December 8, 2008. The data to be presented at these well-regarded medical conferences highlight the unique clinical potential of ACE-011.
